TargTex
Business Services · Portugal · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Avenida Tenente Valadim 2ºF No 17, Torre...Phone Number
+351 217904711Website
www.targtex.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About TargTex
TargTex is focused on developing localized therapies for hard-to-treat tumors, particularly targeting glioblastoma. The company aims to create innovative treatments by aligning scientists, physicians, and patients, and has established collaborations with leading institutions globally. Their lead product, TTX101, has received orphan-drug designation from the FDA for use in malignant gliomas. TargTex is dedicated to improving the quality of life for glioblastoma patients by providing them with effective treatment options.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TargTex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
TargTex, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once TargTex has new funding data
Check out if TargTex is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when TargTex launches new products
Check if TargTex has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on TargTex recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if TargTex had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at TargTex
Recommended Actions
Reach out to Masked Content who joined TargTex as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
TargTex is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
TargTex is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about TargTex.
TargTex Tech Stack
A closer look at the technologies used by TargTex
See more technologies
TargTex News & Media
TargTex to present Tumour Eradication in Rodents from its Nanoformed Glioblastoma drug
Press release Nanoform Finland Plc October 17, 2022 08:10 a.m. Finnish time / 07:10 a.m. Swedish time TargTex to present Tumour Eradication in Rodents from its Nanoformed Glioblastoma drug Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, together with TargTex, a European biotech company, will present highly promising in-vivo data, enabled by nanoformed drug product for the treatment of Glioblastoma. This data was generated for a planned Phase1/2a clinical trialNanoform signs GMP manufacturing program with TargTex following formulation success
Press release Nanoform Finland Plc February 4, 2022 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform signs GMP manufacturing program with TargTex following formulation success Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed a GMP[1] manufacturing program (clinical development) to enhance TargTex’s Glioblastoma multiforme drug candidate. The program starts with a PoP (Proof of Process) phase. This follows a successful PoC
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TargTex
Sign Up For FreeTo access detailed company insights
TargTex is focused on developing localized therapies for hard-to-treat tumors, particularly targeting glioblastoma. The company aims to create innovative treatments by aligning scientists, physicians, and patients, and has established collaborations with leading institutions globally. Their lead product, TTX101, has received orphan-drug designation... Read More
